Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ROIV is expected to report earnings to rise 20.65% to -31 cents per share on November 16
Q3'26
Est.
$-0.31
Q2'26
Beat
by $0.04
Q1'26
Beat
by $0.57
Q4'25
Missed
by $0.07
Q3'25
Beat
by $0.15
The last earnings report on August 06 showed earnings per share of -25 cents, beating the estimate of -30 cents. With 3.69M shares outstanding, the current market capitalization sits at 26.24B.